

SELL TP: Rs 1,325 | ▼ 9%

SUPREME INDUSTRIES

Plastic Products

Margin expansion largely inventory-led; cut to SELL

Supreme Industries' (SI) Q2FY21 revenue grew 8% YoY, aided by a 1% rise in volumes. EBITDA margins expanded 500bps YoY to 18.6% on lower RM cost and other expense. EBITDA/PBT grew 48%/76% YoY. Management did not proffer FY21 guidance due to sustained Covid uncertainty. We hike FY21-FY23 earnings 9-49% due to the above-expected Q2 and raise our target P/E to 28x (from 27x). Rolling over, we have a revised Dec'21 TP of Rs 1,325 (vs. Rs 1,120). At 29.8x FY23E P/E, valuations look rich – cut from REDUCE to SELL.

Volumes flattish: SI's revenue grew 8% YoY to Rs 13.7bn in Q2. Plastic piping/ industrials/packaging revenues increased 4%/7%/11% YoY, whereas the consumer segment declined 1%. Volume growth came from industrials (+13.4% YoY) and packaging (+10.6%); piping declined 1.8%, resulting in blended volume growth of 1.4% YoY. Management indicated a demand revival for housing pipes from September and anticipates further improvement provided the pandemic situation does not worsen.

Inventory gains aid margins: SI's operating margins expanded 500bps YoY to 18.6% due to lower raw material cost (-425bps) and other expenditure (-48bps). Gross margins increased in Q2 mainly from inventory gains due to rising PVC resin prices and a better product mix. EBITDA/PBT for the quarter thus rose 48%/76% YoY. Per management, recent cost control measures would continue to aid margins, though SI could face inventory losses in Q4 when PVC prices likely normalise.

Downgrade to SELL: Though we like SI for its strong brand, comprehensive portfolio and sound balance sheet, we find current valuations of 29.8x FY23E P/E rich and hence downgrade the stock from REDUCE to SELL. Our revised Dec'21 TP stands at Rs 1,325.

KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	56,086	55,087	54,211	61,249	67,734
EBITDA (Rs mn)	7,812	8,563	8,100	9,334	10,556
Adj. net profit (Rs mn)	3,683	4,866	4,534	5,429	6,212
Adj. EPS (Rs)	29.0	38.3	35.7	42.7	48.9
Adj. EPS growth (%)	(13.2)	32.1	(6.8)	19.8	14.4
Adj. ROAE (%)	18.2	22.0	19.1	20.6	21.2
Adj. P/E (x)	50.3	38.1	40.9	34.1	29.8
EV/EBITDA (x)	23.5	21.5	22.7	19.7	17.5

Source: Company, BOBCAPS Research

BOB Capital Markets Ltd is a wholly owned subsidiary of Bank of Baroda

Important disclosures, including any required research certifications, are provided at the end of this report.

28 October 2020

Arun Baid research@bobcaps.in

Ticker/Price	SI IN/Rs 1,459
Market cap	US\$ 2.5bn
Shares o/s	127mn
3M ADV	US\$1.4mn
52wk high/low	Rs 1,500/Rs 773
Promoter/FPI/DII	49%/9%/42%
Source: NSE	

STOCK PERFORMANCE



Source: NSE





FIG 1 - CONSOLIDATED QUARTERLY PERFORMANCE

(Rs mn)	Q2FY21	Q2FY20	YoY (%)	Q1FY21	Q₀Q (%)	H1FY21	H1FY20	Y₀Y (%)
Total revenues	13,748	12,709	8.2	10,539	30.4	24,287	27,077	(10.3)
Total raw material consumed	8,486	8,384	1.2	7,544	12.5	16,030	18,411	(12.9)
% of sales	61.7	66.0	(424bps)	71.6	(985bps)	66.0	68.0	(199bps)
Employee exps	727	685	6.1	633	14.9	1,360	1,371	(0.8)
% of sales	5.3	5.4	(10bps)	6.0	(72bps)	5.6	5.1	53bps
Power & fuel expense	535	519	3.1	349	53.5	884	1069	(17.3)
% of sales	3.9	4.1	(19bps)	3.3	58bps	3.6	3.9	(31bps)
Other exp	1,441	1,393	3.5	842	71.0	2,283	2,825	(19.2)
% of sales	10.5	11.0	(48bps)	8.0	249bps	9.4	10.4	(103bps)
Total expenditure	11,189	10,981	1.9	9,368	19.4	20,557	23,676	(13.2)
% of sales	81.4	86.4	(501bps)	88.9	(750bps)	84.6	87.4	(279bps)
EBITDA	2,559	1,728	48.1	1,171	118.5	3,730	3,402	9.6
% of sales	18.6	13.6	501bps	11.1	750bps	15.4	12.6	279bps
Depreciation	523	517	1.1	508	3.0	1,031	1,013	1.8
Other income	1	5	(85.2)	3	(71.4)	4	6	(36.8)
Interest cost	25	71	(64.8)	78	(68.0)	103	103	(0.5)
PBT	2,011	1,145	75.6	588	242.0	2,600	2,291	13.5
Taxes	527.0	(140.4)	(475.4)	146.4	260.0	673.4	259.1	159.9
Effective tax rate (%)	26	(12)	3,846bps	25	131bps	26	11	1,460bps
PAT	1,484	1,286	15.4	442	236.0	1,926	2,032	(5.2)
Share of profit of associate	265	110	141.2	(37)	(826.3)	229	235	(2.6)
RPAT	1,750	1,396	25.3	405	331.7	2,155	2,267	(5.0)

Source: Company, BOBCAPS Research

FIG 2 – SEGMENTAL PERFORMANCE

(Rs mn)	Q2FY21	Q2FY20	YoY (%)	Q1FY21	QºQ (%)	H1FY21	H1FY20	Y₀Y (%)
(1) Segment revenue								
Plastic Piping Products	8,473	8,115	4.4	7,646	10.8	16,118	17,095	(5.7)
Industrial Products	1,815	1,691	7.3	705	157.4	2,519	3,574	(29.5)
Packaging Products	2,198	1,980	11.1	1,876	17.2	4,074	4,431	(8.0)
Consumer Products	855	863	(1.0)	280	205.3	1,135	1,837	(38.2)
Others	408	60	576.1	33	1154.5	440	142	210.9
Net Revenue from Operations	13,748	12,709	8.2	10,539	30.4	24,287	27,077	(10.3)
(2) EBIT								
Plastic Piping Products	1,475	1,099	34.3	665	122.0	2,140	1,882	13.7
Industrial Products	120	(20)	(711.7)	(76)	(257.8)	44	101	(56.4)
Packaging Products	256	38	569.9	183	39.6	439	244	79.9
Consumer Products	127	110	15.8	(45)	(382.0)	82	238	(65.6)
Others	100	3	3362.1	(1)	(8,466.7)	99	1	12,300.0
Total Segment Profit before Interest and Tax	2,079	1,230	69.0	726	186.4	2,804	2,465	13.8
Margins (%)								
Plastic Piping Products	17.4	13.5	388bps	8.7	872bps	13.3	11.0	227bps
Industrial Products	6.6	(1.2)	777bps	(10.8)	1,739bps	1.7	2.8	(108bps)
Packaging Products	11.6	1.9	971bps	9.8	187bps	10.8	5.5	527bps
Consumer Products	14.8	12.7	215bps	(16.1)	3,092bps	7.2	13.0	(575bps)








FIG 3 - CONSOLIDATED REVENUE GROWTH

FIG 5 – CONSOLIDATED EBITDA GROWTH




Source: BOBCAPS Research, Company

FIG 7 – VOLUME GROWTH




Source: BOBCAPS Research, Company

FIG 4 – REVENUE MIX



Source: BOBCAPS Research

FIG 6 - CONSOLIDATED EBITDA MARGIN






FIG 8 – REVENUE SHARE OF VALUE-ADDED PRODUCTS

Source: BOBCAPS Research, Company

FIG 9 – SEGMENTAL VOLUMES

(MT)	Q2FY21	Q2FY20	YoY (%)	Q1FY21	Q₀Q (%)
Plastic piping	66,609	67,812	(1.8)	74,992	(11.2)
Packaging Products	12,239	11,062	10.6	10,182	20.2
Industrial Products	11,285	9,953	13.4	4,770	136.6
Consumer Products	4,703	4,673	0.6	1,507	212.1
Total	94,836	93,500	1.4	91,451	3.7



Earnings call highlights

- During Q2FY21, demand picked up across SI's product categories as the economy opened up. Plant utilisation reached pre-Covid levels during the quarter. October also looks to be a growth month across categories.
- Piping demand from the housing segment has revived across markets, except the MMR.
- Management expects demand to continue improving MoM unless the Covid-19 situation worsens. SI nevertheless refrained from giving out FY21 guidance due to persisting pandemic uncertainties.
- PVC prices have been going up and may continue to do so till Q3FY21. Management expects prices to soften from January.
- Due to higher PVC prices, dealer stocking has been limited which has resulted in the company carrying higher stocks.
- SI had inventory gains in Q2 due to the rising PVC prices but expects a reversal in Q4 when prices are likely to fall.
- Prices of all other raw materials besides PVC are range-bound.
- Management believes some margin gains will be sustained due to recent cost and operational measures.
- SI believes it gained market share in pipes during H1. The PVC resin market declined by 25% in the first half of the year.
- The company plans to set up factories in Assam and Tamil Nadu and is in discussions for buying land there. The Odisha plant land deal should be concluded by Nov'20.
- SI is focused on increasing its dealer network and has added ~85 dealers in FY21, taking its total count to 1,300.



Valuation methodology

SI is a play on India's growing housing and consumer market, backed by a strong brand, comprehensive product portfolio and wide distribution reach. A healthy operating margin profile (14-15%), impressive return ratios (ROE of 21% in FY23E) and negligible debt make the stock attractive.

Post Q2, we increase FY21/FY22/FY23 earnings estimates by 49%/12%/9%. Our EBITDA revision in FY21 is partly driven by inventory gains whereas PAT revision is higher than EBITDA due to the above-expected performance at associate company Supreme Petrochem. Though we like SI for its product portfolio and strong balance sheet, current valuations of 29.8x FY23E P/E appear rich. We downgrade the stock from REDUCE to SELL and roll forward to a revised Dec'21 target price of Rs 1,325 (earlier Rs 1,120). We now value SI at a one-year forward P/E of 28x (earlier 27x), in line with the five-year average.

FIG 10 - REVISED ESTIMATES

	Old			New		(Change (%)	
FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E
47,417	58,151	65,160	54,211	61,249	67,734	14.3	5.3	4.0
6,364	8,629	9,915	8,100	9,334	10,556	27.3	8.2	6.5
3,043	4,831	5,678	4,534	5,429	6,212	49.0	12.4	9.4
	47,417 6,364	FY21E FY22E 47,417 58,151 6,364 8,629	FY21E FY22E FY23E 47,417 58,151 65,160 6,364 8,629 9,915	FY21E FY22E FY23E FY21E 47,417 58,151 65,160 54,211 6,364 8,629 9,915 8,100	FY21E FY22E FY23E FY21E FY22E 47,417 58,151 65,160 54,211 61,249 6,364 8,629 9,915 8,100 9,334	FY21E FY22E FY23E FY21E FY22E FY23E 47,417 58,151 65,160 54,211 61,249 67,734 6,364 8,629 9,915 8,100 9,334 10,556	FY21E FY22E FY23E FY23E FY21E FY23E FY23E FY21E 47,417 58,151 65,160 54,211 61,249 67,734 14.3 6,364 8,629 9,915 8,100 9,334 10,556 27.3	FY21E FY22E FY23E FY21E FY21E FY23E FY23E <th< td=""></th<>

Source: BOBCAPS Research




FIG 11 – RELATIVE STOCK PERFORMANCE

Source: NSE

Key risks

Key upside risks to our call are:

- above-expected margins in the event of reduced raw material cost, and
- the unorganised market seeing a worse fall than anticipated.



FINANCIALS

Income Statement

Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue	56,086	55,087	54,211	61,249	67,734
EBITDA	7,812	8,563	8,100	9,334	10,556
Depreciation	(1,835)	(2,057)	(2,194)	(2,395)	(2,644)
EBIT	5,977	6,506	5,906	6,939	7,912
Net interest income/(expenses)	(336)	(297)	(210)	(95)	(60)
Other income/(expenses)	56	84	88	123	148
Exceptional items	803	(192)	0	0	0
EBT	5,697	6,293	5,784	6,968	8,000
Income taxes	(2,158)	(1,739)	(1,560)	(1,868)	(2,138)
Extraordinary items	0	0	0	0	0
Min. int./Inc. from associates	144	312	310	330	350
Reported net profit	4,486	4,674	4,534	5,429	6,212
Adjustments	(803)	192	0	0	0
Adjusted net profit	3,683	4,866	4,534	5,429	6,212
Accounts payables	5,574	5,475	5,198	5,873	6,495
Balance Sheet Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21E	FY22E	FY23E
. ,	,		,	,	,
Other current liabilities Provisions	2,123 240	2,347	2,079	2,349	2,598 474
Debt funds		313		429	
Debt funds	1,613	4,113	1,500	400	
	0.42	0.47	0.47	0.47	200
Other liabilities	843	947	947	947	947
Equity capital	254	254	254	254	947 254
Equity capital Reserves & surplus	254 21,286	254 22,358	254 24,697	254 27,499	947 254 30,704
Equity capital Reserves & surplus Shareholders' fund	254 21,286 21,540	254 22,358 22,612	254 24,697 24,951	254 27,499 27,753	947 254 30,704 30,958
Equity capital Reserves & surplus Shareholders' fund Total liabilities and equities	254 21,286 21,540 31,932	254 22,358 22,612 35,807	254 24,697 24,951 35,055	254 27,499 27,753 37,751	947 254 30,704 30,958 41,672
Equity capital Reserves & surplus Shareholders' fund Total liabilities and equities Cash and cash eq.	254 21,286 21,540 31,932 373	254 22,358 22,612 35,807 1,614	254 24,697 24,951 35,055 157	254 27,499 27,753 37,751 458	947 254 30,704 30,958 41,672 1,424
Equity capital Reserves & surplus Shareholders' fund Total liabilities and equities Cash and cash eq. Accounts receivables	254 21,286 21,540 31,932 373 3,874	254 22,358 22,612 35,807 1,614 3,128	254 24,697 24,951 35,055 157 3,565	254 27,499 27,753 37,751 458 4,363	947 254 30,704 30,958 41,672 1,424 4,825
Equity capital Reserves & surplus Shareholders' fund Total liabilities and equities Cash and cash eq. Accounts receivables Inventories	254 21,286 21,540 31,932 373 3,874 7,504	254 22,358 22,612 35,807 1,614 3,128 8,906	254 24,697 24,951 35,055 157 3,565 8,169	254 27,499 27,753 37,751 458 4,363 8,390	947 254 30,704 30,958 41,672 1,424 4,825 9,279
Equity capital Reserves & surplus Shareholders' fund Total liabilities and equities Cash and cash eq. Accounts receivables Inventories Other current assets	254 21,286 21,540 31,932 373 3,874 7,504 1,847	254 22,358 22,612 35,807 1,614 3,128 8,906 2,379	254 24,697 24,951 35,055 157 3,565 8,169 2,079	254 27,499 27,753 37,751 458 4,363 8,390 2,349	947 254 30,704 30,958 41,672 1,424 4,825 9,279 2,598
Equity capital Reserves & surplus Shareholders' fund Total liabilities and equities Cash and cash eq. Accounts receivables Inventories Other current assets Investments	254 21,286 21,540 31,932 373 3,874 7,504 1,847 2,223	254 22,358 22,612 35,807 1,614 3,128 8,906 2,379 2,773	254 24,697 24,951 35,055 157 3,565 8,169 2,079 2,773	254 27,499 27,753 37,751 458 4,363 8,390 2,349 2,773	947 254 30,704 30,958 41,672 1,424 4,825 9,279 2,598 2,773
Equity capital Reserves & surplus Shareholders' fund Total liabilities and equities Cash and cash eq. Accounts receivables Inventories Other current assets Investments Net fixed assets	254 21,286 21,540 31,932 373 3,874 7,504 1,847 2,223 15,014	254 22,358 22,612 35,807 1,614 3,128 8,906 2,379 2,773 15,917	254 24,697 24,951 35,055 157 3,565 8,169 2,079 2,773 17,223	254 27,499 27,753 37,751 458 4,363 8,390 2,349 2,773 18,328	947 254 30,704 30,958 41,672 1,424 4,825 9,279 2,598 2,773 19,684
Equity capital Reserves & surplus Shareholders' fund Total liabilities and equities Cash and cash eq. Accounts receivables Inventories Other current assets Investments	254 21,286 21,540 31,932 373 3,874 7,504 1,847 2,223	254 22,358 22,612 35,807 1,614 3,128 8,906 2,379 2,773	254 24,697 24,951 35,055 157 3,565 8,169 2,079 2,773	254 27,499 27,753 37,751 458 4,363 8,390 2,349 2,773	947 254 30,704 30,958 41,672 1,424 4,825 9,279 2,598 2,773



Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21E	FY22E	FY23
Net income + Depreciation	6,322	6,731	6,728	7,824	8,85
Interest expenses	336	297	210	95	6
Non-cash adjustments	0	0	0	0	(
Changes in working capital	674	(989)	123	(296)	(683
Other operating cash flows	0	0	0	0	(
Cash flow from operations	7,331	6,038	7,061	7,623	8,23
Capital expenditures	(3,661)	(2,953)	(3,500)	(3,500)	(4,000
Change in investments	287	(550)	0	0	(
Other investing cash flows	71	(211)	0	0	(
Cash flow from investing	(3,304)	(3,714)	(3,500)	(3,500)	(4,000
Equities issued/Others	0	0	0	0	(
Debt raised/repaid	(851)	2,500	(2,613)	(1,100)	(200
Interest expenses	(336)	(297)	(210)	(95)	(60
Dividends paid	(1,991)	(3,522)	(2,194)	(2,628)	(3,007
Other financing cash flows	(840)	235	0	0	(
Cash flow from financing	(4,017)	(1,084)	(5,017)	(3,823)	(3,267
Changes in cash and cash eq.	10	1,240	(1,456)	301	96
Closing cash and cash eq.	373	1,613	157	458	1,42

Per Share

Y/E 31 Mar (Rs)	FY19A	FY20A	FY21E	FY22E	FY23E
Reported EPS	35.3	36.8	35.7	42.7	48.9
Adjusted EPS	29.0	38.3	35.7	42.7	48.9
Dividend per share	13.0	14.0	14.3	17.1	19.6
Book value per share	169.6	178.0	196.4	218.5	243.7

Valuations Ratios

Y/E 31 Mar (x)	FY19A	FY20A	FY21E	FY22E	FY23E
EV/Sales	3.3	3.3	3.4	3.0	2.7
EV/EBITDA	23.5	21.5	22.7	19.7	17.5
Adjusted P/E	50.3	38.1	40.9	34.1	29.8
P/BV	8.6	8.2	7.4	6.7	6.0

DuPont Analysis

Y/E 31 Mar (%)	FY19A	FY20A	FY21E	FY22E	FY23E
Tax burden (Net profit/PBT)	56.7	79.8	78.4	77.9	77.7
Interest burden (PBT/EBIT)	108.8	93.8	97.9	100.4	101.1
EBIT margin (EBIT/Revenue)	10.7	11.8	10.9	11.3	11.7
Asset turnover (Revenue/Avg TA)	183.0	162.6	153.0	168.3	170.6
Leverage (Avg TA/Avg Equity)	1.5	1.5	1.5	1.4	1.4
Adjusted ROAE	18.2	22.0	19.1	20.6	21.2

Source: Company, BOBCAPS Research | Note: TA = Total Assets



Ratio Analysis					
Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
YoY growth (%)					
Revenue	13.0	(1.8)	(1.6)	13.0	10.6
EBITDA	(0.4)	9.6	(5.4)	15.2	13.1
Adjusted EPS	(13.2)	32.1	(6.8)	19.8	14.4
Profitability & Return ratios (%)					
EBITDA margin	13.9	15.5	14.9	15.2	15.6
EBIT margin	10.7	11.8	10.9	11.3	11.7
Adjusted profit margin	6.6	8.8	8.4	8.9	9.2
Adjusted ROAE	18.2	22.0	19.1	20.6	21.2
ROCE	17.9	18.7	16.2	18.6	19.6
Working capital days (days)					
Receivables	25	23	23	24	25
Inventory	69	84	87	75	72
Payables	40	43	42	39	39
Ratios (x)					
Gross asset turnover	2.1	1.9	1.7	1.7	1.7
Current ratio	1.4	1.3	1.5	1.7	1.9
Net interest coverage ratio	17.8	21.9	28.1	73.0	131.9
Adjusted debt/equity	0.1	0.1	0.1	0.0	0.0



Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


ADD - Expected return from >+5% to +15%

REDUCE – Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

RATINGS AND TARGET PRICE (3-YEAR HISTORY): SUPREME INDUSTRIES (SI IN)



B - Buy, A - Add, R - Reduce, S - Sell

Rating distribution

As of 30 September 2020, out of 104 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 54 have BUY ratings, 18 have ADD ratings, 10 are rated REDUCE and 22 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH00000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations

SUPREME INDUSTRIES



expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.